December 20, 2011
Meiji Seika Pharma announced on December 19 that it had entered into a licensing agreement with Dong-A Pharmaceutical of South Korea to develop and market in Japan udenafil, a selective phosphodiesterase type 5 (PDE5) inhibitor discovered by Dong-A. Meiji Seika...read more